Офтальмохирургия. 2017; : 88-92
СОВРЕМЕННЫЕ АСПЕКТЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ ПОЛИПОИДНОЙ ХОРИОИДАЛЬНОЙ ВАСКУЛОПАТИИ
https://doi.org/10.25276/0235-4160-2017-1-88-92Аннотация
Полипоидная хориоидальная васкулопатия (ПХВ) представляет собой относительно редкий подтип возрастной макулярной дегенерации (ВМД), сложный в плане дифференциальной диагностики и резистентный в отношении общепринятой терапии ВМД (анти-VEGF-препараты). Морфологический субстрат ПХВ – измененные сосуды хориоидеи с расширениями на концах – полипами. В настоящем обзоре литературы рассмотрены современные представления о распространенности, факторах риска, патогенезе ПХВ, комплексе диагностических методов исследования, а также основных подходах к лечению данной патологии.
Список литературы
1. Соломин В.А. Современные неинвазивные методы диагностики и комбинированное лечение пациентов с субмакулярной неоваскулярной мембраной: Дис. … канд. мед. наук. – М., 2014. –129 с.
2. Терещенко А.В., Белый Ю.А., Володин П.Л., Каплан М.А. Фотодинамическая терапия с фотосенсибилизатором «Фотодитазин» в офтальмологии. – Калуга, 2008. – 288 с.
3. Шаимов Т.Б. Современные методы диагностики полипоидной хориоидальной васкулопатии // Современные технологии и офтальмологии. – 2015. – № 3. – С. 181-183.
4. Шпак А.А., Качалина Г.Ф., Педанова Е.К. Сравнительный анализ результатов микропериметрии и традиционной компьютерной периметрии в норме // Вестник офтальмологии. – 2009. – № 3 (125). – С. 31-33.
5. Akaza E., Yuzawa M., Mori R. Three-year followup results of photodynamic therapy for polypoidal choroidal vasculopathy // Jpn. J. Ophthalmol. – 2011 – Vol. 55. – P. 39-44.
6. Cackett P., Wong D., Yeo I. A classification system for polypoidal choroidal vasculopathy // Retina. – 2009. – Vol. 29, № 2. – P. 187-191.
7. Chang W., Noh D.H., Sagong M. et al. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population // Mol. Vis. – 2013. – Vol. 19. – P. 702-709.
8. Cheung C.M., Yang E., Lee W.K. et al. The natural history of polypoidal choroidal vasculopathy: A multicenter series of untreated Asian patients // Graefes Arch. Clin. Exp. Ophthalmol. – 2015. – Vol. 253, № 12. – P. 2075-2085.
9. Ciardella A.P., Donsoff I.M., Huang S.J. et al. Polypoidal choroidal vasculopathy // Surv. Ophthalmol. – 2004. – Vol. 49. – P. 25-37.
10. Colin S.H., Ngo W.K., Lim L.W., Lim T.H. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes // Br. J. Ophthalmol. – 2014. – Vol. 98, № 11. – P. 1528-1533.
11. Gomi F., Sawa M., Mitarai K. et al. Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography // Graefes Arch. Clin. Exp. Ophthalmol. – 2007. – Vol. 245, № 10. – P. 1421-1427.
12. Hayashi H., Yamashiro K., Gotoh N. et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation // Invest. Ophthalmol. Vis. Sci. – 2010. – Vol. 51. – P. 5914-5919.
13. Japanese Study Group of Polypoidal Choroidal Vasculopathy Criteria for diagnosis of polypoidal choroidal vasculopathy // Nippon Ganka Gakkai Zasshi. – 2005. – Vol. 109. – P. 417-427.
14. Kang H.M., Koh H.J. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2013. – Vol. 156. – P. 652-660.
15. Kang H.M., Kim Y.M., Koh H.J. Five-year followup results of photodynamic therapy for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2013. – Vol. 155. – P. 438-447.
16. Kim A., Gomi F., Sakaguchi H. et al. Sub-Tenon’s injection of triamcinolone acetonide for choroidal neovascularization // Nippon Ganka Gakkai Zasshi. – 2006. – Vol. 110, № 1. – P. 19-24.
17. Kim J.Y., Kwon O.W., Oh H.S. et al. Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2016. – Vol. 254, № 8. – P. 1505-1510.
18. Kim S.W., Oh J., Kwon S.S. et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy // Retina. – 2011. – Vol. 31. – P. 1904-1911.
19. Koh A., Lee W.K., Chen L.J et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy // Retina. – 2012. – Vol. 32, № 8. – P. 1453-1464.
20. Lee M.W., Yeo I., Wong D., Ang C.L. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy // Eye. – 2009. – Vol. 23. – P. 145-148.
21. Liu Y., Wen F., Huang S. et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients // Graefes Arch. Clin. Exp. Ophthalmol. – 2007. – Vol. 245. – P. 1441-1445.
22. Mori R., Yuzawa M., Lee Z. et al. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy // Graefes Arch. Clin. Exp. Ophthalmol. – 2010. – Vol. 248. – P. 1233-1239.
23. Nakashizuka H., Mitsumata M., Okisaka S. et al. Clinicopathological findings of polypoidal choroidal vasculopathy // Invest. Ophthalmol. Vis. Sci. – 2008. – Vol. 49, № 11. – P. 4729-4737.
24. Oishi A., Kojima H., Mandai M. et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results // Am. J. Ophthalmol. – 2013. – Vol. 156. – P. 644-651.
25. Ojima Y., Tsujikawa A., Otani A. et al. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2006. – Vol. 141. – P. 958-960.
26. Rishi P., Rishi E., Mathur G., Raval V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normal // Eye (Lond.). – 2013. – Vol. 27. – P. 1038-1043.
27. Sato T., Kishi S., Watanabe G. et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy // Retina. – 2007. – Vol. 27. – P. 589-594.
28. Schmidt-Erfurth U., Miller J., Sickenberg M. et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples // Graefes Arch. Clin. Exp. Ophthalmol. – 1998. – Vol. 236, № 5. – P. 365-374.
29. Sho K., Takahashi K., Yamada H. et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics // Arch. Ophthalmol. – 2003. – Vol. 121, № 10. – P. 1392-1396.
30. Terasaki H., Miyake Y., Suzuki T. et al. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation // Br. J. Ophthalmol. – 2002. – Vol. 86, № 3. – P. 321-327.
31. Tsujikawa A., Sasahara M., Otani A. et al. Pigment epithelial detachment in polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2007. – Vol. 143. – P. 102-111.
32. Yamagishi T., Koizumi H., Yamazaki T. et al. Fundus autofluorescence in polypoidal choroidal vasculopathy // Ophthalmology. – 2012. – Vol. 119. – P. 1650-1657.
33. Yannuzzi L.A., Freund K.B., Goldbaum M. et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy // Ophthalmology. – 2000. – Vol. 107. – P. 767-777.
34. Yannuzzi L.A., Sorenson J., Spaide R.F. et al. Idiopathic polypoidal choroidal vasculopathy (IPCV) // Retina. – 1990. – Vol. 10. – P. 1-8.
35. Yannuzzi L.A., Wong D.W., Sforzolini B.S. et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration // Arch. Ophthalmol. – 1999. – Vol. 117. – P. 1503-1510.
36. Yodoi Y., Tsujikawa A., Kameda T. et al. Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2007. – Vol. 143, № 6. – P. 984-994.
37. Yuzawa M., Mori R., Kawamura A. The origins of polypoidal choroidal vasculopathy // Br. J. Ophthalmol. – 2005. – Vol. 89. – P. 602-607.
Fyodorov Journal of Ophthalmic Surgery. 2017; : 88-92
CURRENT ASPECTS OF DIAGNOSIS AND TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY
https://doi.org/10.25276/0235-4160-2017-1-88-92Abstract
Polypoidal choroidal vasculopathy (PCV) is the rare subtype of agerelated macular degeneration (AMD), which is hard to diagnose and it is resistant to standard anti-VEGF treatment of AMD. The morphological base of PCV is the pathology of choroid vessels with formation of expansions on their ends – polyps. This literature review presented a current conception of the prevalence, risk factors, pathogenesis, diagnostic techniques and the main treatment approaches of this disease.
References
1. Solomin V.A. Sovremennye neinvazivnye metody diagnostiki i kombinirovannoe lechenie patsientov s submakulyarnoi neovaskulyarnoi membranoi: Dis. … kand. med. nauk. – M., 2014. –129 s.
2. Tereshchenko A.V., Belyi Yu.A., Volodin P.L., Kaplan M.A. Fotodinamicheskaya terapiya s fotosensibilizatorom «Fotoditazin» v oftal'mologii. – Kaluga, 2008. – 288 s.
3. Shaimov T.B. Sovremennye metody diagnostiki polipoidnoi khorioidal'noi vaskulopatii // Sovremennye tekhnologii i oftal'mologii. – 2015. – № 3. – S. 181-183.
4. Shpak A.A., Kachalina G.F., Pedanova E.K. Sravnitel'nyi analiz rezul'tatov mikroperimetrii i traditsionnoi komp'yuternoi perimetrii v norme // Vestnik oftal'mologii. – 2009. – № 3 (125). – S. 31-33.
5. Akaza E., Yuzawa M., Mori R. Three-year followup results of photodynamic therapy for polypoidal choroidal vasculopathy // Jpn. J. Ophthalmol. – 2011 – Vol. 55. – P. 39-44.
6. Cackett P., Wong D., Yeo I. A classification system for polypoidal choroidal vasculopathy // Retina. – 2009. – Vol. 29, № 2. – P. 187-191.
7. Chang W., Noh D.H., Sagong M. et al. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population // Mol. Vis. – 2013. – Vol. 19. – P. 702-709.
8. Cheung C.M., Yang E., Lee W.K. et al. The natural history of polypoidal choroidal vasculopathy: A multicenter series of untreated Asian patients // Graefes Arch. Clin. Exp. Ophthalmol. – 2015. – Vol. 253, № 12. – P. 2075-2085.
9. Ciardella A.P., Donsoff I.M., Huang S.J. et al. Polypoidal choroidal vasculopathy // Surv. Ophthalmol. – 2004. – Vol. 49. – P. 25-37.
10. Colin S.H., Ngo W.K., Lim L.W., Lim T.H. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes // Br. J. Ophthalmol. – 2014. – Vol. 98, № 11. – P. 1528-1533.
11. Gomi F., Sawa M., Mitarai K. et al. Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography // Graefes Arch. Clin. Exp. Ophthalmol. – 2007. – Vol. 245, № 10. – P. 1421-1427.
12. Hayashi H., Yamashiro K., Gotoh N. et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation // Invest. Ophthalmol. Vis. Sci. – 2010. – Vol. 51. – P. 5914-5919.
13. Japanese Study Group of Polypoidal Choroidal Vasculopathy Criteria for diagnosis of polypoidal choroidal vasculopathy // Nippon Ganka Gakkai Zasshi. – 2005. – Vol. 109. – P. 417-427.
14. Kang H.M., Koh H.J. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2013. – Vol. 156. – P. 652-660.
15. Kang H.M., Kim Y.M., Koh H.J. Five-year followup results of photodynamic therapy for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2013. – Vol. 155. – P. 438-447.
16. Kim A., Gomi F., Sakaguchi H. et al. Sub-Tenon’s injection of triamcinolone acetonide for choroidal neovascularization // Nippon Ganka Gakkai Zasshi. – 2006. – Vol. 110, № 1. – P. 19-24.
17. Kim J.Y., Kwon O.W., Oh H.S. et al. Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2016. – Vol. 254, № 8. – P. 1505-1510.
18. Kim S.W., Oh J., Kwon S.S. et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy // Retina. – 2011. – Vol. 31. – P. 1904-1911.
19. Koh A., Lee W.K., Chen L.J et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy // Retina. – 2012. – Vol. 32, № 8. – P. 1453-1464.
20. Lee M.W., Yeo I., Wong D., Ang C.L. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy // Eye. – 2009. – Vol. 23. – P. 145-148.
21. Liu Y., Wen F., Huang S. et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients // Graefes Arch. Clin. Exp. Ophthalmol. – 2007. – Vol. 245. – P. 1441-1445.
22. Mori R., Yuzawa M., Lee Z. et al. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy // Graefes Arch. Clin. Exp. Ophthalmol. – 2010. – Vol. 248. – P. 1233-1239.
23. Nakashizuka H., Mitsumata M., Okisaka S. et al. Clinicopathological findings of polypoidal choroidal vasculopathy // Invest. Ophthalmol. Vis. Sci. – 2008. – Vol. 49, № 11. – P. 4729-4737.
24. Oishi A., Kojima H., Mandai M. et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results // Am. J. Ophthalmol. – 2013. – Vol. 156. – P. 644-651.
25. Ojima Y., Tsujikawa A., Otani A. et al. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2006. – Vol. 141. – P. 958-960.
26. Rishi P., Rishi E., Mathur G., Raval V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normal // Eye (Lond.). – 2013. – Vol. 27. – P. 1038-1043.
27. Sato T., Kishi S., Watanabe G. et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy // Retina. – 2007. – Vol. 27. – P. 589-594.
28. Schmidt-Erfurth U., Miller J., Sickenberg M. et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples // Graefes Arch. Clin. Exp. Ophthalmol. – 1998. – Vol. 236, № 5. – P. 365-374.
29. Sho K., Takahashi K., Yamada H. et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics // Arch. Ophthalmol. – 2003. – Vol. 121, № 10. – P. 1392-1396.
30. Terasaki H., Miyake Y., Suzuki T. et al. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation // Br. J. Ophthalmol. – 2002. – Vol. 86, № 3. – P. 321-327.
31. Tsujikawa A., Sasahara M., Otani A. et al. Pigment epithelial detachment in polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2007. – Vol. 143. – P. 102-111.
32. Yamagishi T., Koizumi H., Yamazaki T. et al. Fundus autofluorescence in polypoidal choroidal vasculopathy // Ophthalmology. – 2012. – Vol. 119. – P. 1650-1657.
33. Yannuzzi L.A., Freund K.B., Goldbaum M. et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy // Ophthalmology. – 2000. – Vol. 107. – P. 767-777.
34. Yannuzzi L.A., Sorenson J., Spaide R.F. et al. Idiopathic polypoidal choroidal vasculopathy (IPCV) // Retina. – 1990. – Vol. 10. – P. 1-8.
35. Yannuzzi L.A., Wong D.W., Sforzolini B.S. et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration // Arch. Ophthalmol. – 1999. – Vol. 117. – P. 1503-1510.
36. Yodoi Y., Tsujikawa A., Kameda T. et al. Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy // Am. J. Ophthalmol. – 2007. – Vol. 143, № 6. – P. 984-994.
37. Yuzawa M., Mori R., Kawamura A. The origins of polypoidal choroidal vasculopathy // Br. J. Ophthalmol. – 2005. – Vol. 89. – P. 602-607.
